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Position PaperSummary
Management of decompensated cirrhosis is currently geared towards the treatment of complications
once they occur. To date there is no established disease-modifying therapy aimed at halting progression
of the disease and preventing the development of complications in patients with decompensated
cirrhosis. The design of clinical trials to investigate new therapies for patients with decompensated
cirrhosis is complex. The population of patients with decompensated cirrhosis is heterogeneous (i.e.,
different etiologies, comorbidities and disease severity), leading to the inclusion of diverse populations in
clinical trials. In addition, primary endpoints selected for trials that include patients with decompensated
cirrhosis are not homogeneous and at times may not be appropriate. This leads to difficulties in
comparing results obtained from different trials. Against this background, the LiverHope Consortium
organized a meeting of experts, the goal of which was to develop recommendations for the design of
clinical trials and to define appropriate endpoints, both for trials aimed at modifying the natural history
and preventing progression of decompensated cirrhosis, as well as for trials aimed at managing the
individual complications of cirrhosis.
© 2020 European Association for the Study of the Liver. Published by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Background
The natural history of cirrhosis is characterized by
an asymptomatic or minimally symptomatic phase
defined by the absence of overt clinical manifes-
tations of the disease, followed by a decom-
pensated phase, characterized by the occurrence of
complications, typically ascites, gastrointestinal
(GI) bleeding, hepatic encephalopathy (HE), and/or
jaundice. Such patients are at risk of bacterial in-
fections and acute kidney injury (AKI). The occur-
rence of decompensated cirrhosis is associated
with reduced survival.1,2 Management of decom-
pensated cirrhosis is based on treatment of indi-
vidual complications once they occur. Most drugs
and therapeutic interventions used in the man-
agement of complications of cirrhosis were intro-
duced decades ago and merely control symptoms;
thus, complications tend to recur after treatment is
discontinued. In fact, with the possible exception of
non-selective beta-blockers (NSBBs) and trans-
jugular intrahepatic portosystemic shunts (TIPS) in
selected populations,3–5 there is no therapeutic
approach that has shown efficacy in slowing theJournal of Hepatology 2021 vol. 74 j 2progression of disease. In this regard, a number of
studies have been performed to investigate new
therapeutic strategies for the management of
specific complications of cirrhosis or the
prevention of disease progression.6–11 The design,
methodology, study population and endpoints of
these trials have been variable and sometimes
difficult to interpret or apply widely. This is partly
due to the complexity of defining target
populations and endpoints in clinical trials for
decompensated cirrhosis. The population of
patients with decompensated cirrhosis is quite
heterogeneous, in terms of etiology, variety of
complications, severity of liver failure,
comorbidities and access to liver transplantation.
Therefore, the populations of patients with
decompensated cirrhosis included in clinical trials
are often diverse, as varied inclusion and
exclusion criteria are used. In addition, primary
endpoints are frequently heterogeneous and
sometimes not appropriate. This leads to
difficulties in the interpretation and comparison00–219
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j.jhep.2020.08.009of results from different studies. Although there
have been a number of initiatives to provide
recommendations for the design and endpoints of
clinical trials in other areas of hepatology,
especially in non-alcoholic fatty liver disease,12–14
these initiatives are lacking in the field of
decompensated cirrhosis.
Therefore, there is an unmet need to stan-
dardize the design and definition of endpoints in
clinical trials in patients with decompensated
cirrhosis. The aim of this document is to provide
expert recommendations to meet that need. The
first part of the document summarises the recom-
mendations for trials aimed at modifying the nat-
ural history of decompensated cirrhosis and
preventing its progression, whereas the second
part summarises the recommendations for trials
targeting individual complications of cirrhosis. The
document focuses on all complications of cirrhosis
with the exception of portal hypertension-related
bleeding, because recommendations for clinical




A literature review was performed by a task force of
10 young investigators from hospitals involved in
the LiverHope Consortium. This task force system-
atically searched PubMed from Jan 1, 1980 to Jan 1,
2019, for clinical trials on decompensated cirrhosis.
Search terms used were “decompensated” and
“cirrhosis”, and a filter for clinical trials was used.
Only English articles were considered. Of the 311
search results, the task force selected the clinical
trials that were considered most relevant based on
the following criteria: published in the first decile
high-impact journals; selected trials investigating
specific therapies or interventions aimed at modi-
fying the natural history of decompensated
cirrhosis; and a clear experimental design targeting
the population of patients with decompensated
cirrhosis. The initial search was reviewed by a se-
nior investigator (PG) and a final selection was
made. These studies were used as a framework for
the meeting and to develop the first part of this
document on trials assessing interventions to
modify the natural history of decompensated
cirrhosis. The same procedure was followed for
every specific complication of cirrhosis presented in
this document.
Literature evidence was summarized and
reviewed in groups of 2 in a 2-day meeting.
Following this, a working document was prepared
and later discussed in depth by all members of the
conference during a 2-day face-to-face meeting in
June 2019.
Meeting of the LiverHope consortium
The meeting was organized by the LiverHope
consortium with the objective of proposingJournal orecommendations for the design and selection of
study populations for clinical trials in decom-
pensated cirrhosis. LiverHope is a 7-nation con-
sortium composed of 9 European hospitals with
extensive experience in hepatology that is aimed at
exploring new therapies for cirrhosis (www.
liverhope-h2020.eu). The Consortium is funded
by the European Commission under the Horizon
20/20 program. Within the consortium, patients
are represented by the European Liver Patients
Association (ELPA). The LiverHope consortium
convened a group of experts including a body of
investigators, members of ELPA, pharmaceutical
industry representatives, medical statisticians, and
health economists, as well as members of the Liv-
erHope external advisory board to participate in a
special workshop. The current position document
summarises the areas of discussion and consensus
among members of the conference.
Methodological aspects for the design of
clinical trials in decompensated cirrhosis
Careful planning and reporting of the design of
clinical trials is essential to achieve robust and
comparable results. Important issues that need to
be considered and detailed when designing and
reporting results from clinical trials include aspects
such as characteristics used to define the target
population, selection and definition of adequate
endpoints and adequate statistical analysis plan-
ning (Table 1). A detailed description of the
methodological and statistical aspects that need to
be considered when designing clinical trials in
patients with decompensated cirrhosis is included
in the supplementary material.
Trials assessing interventions aimed at
modifying the natural history of
decompensated cirrhosis
Recommendations on the population to be
included in these studies should be a balance be-
tween including a homogeneous population and
not being too restrictive, so that the results can be
translated into a large proportion of patients with
decompensated cirrhosis.
In this setting, when defining the target popu-
lation, there is often controversy regarding
whether to include specific patient characteristics,
such as advanced age, severity of liver failure or
specific comorbidities, as part of the exclusion
criteria. The next section includes recommenda-
tions for defining specific characteristics of the
target population. A summary of the recommen-
dations for the target population and endpoints is
provided in Table 2.Target population
Child-Turcotte-Pugh score
The concept of decompensated cirrhosis refers to
patients with cirrhosis and complications of thef Hepatology 2021 vol. 74 j 200–219 201
Table 1. Important information when reporting results of clinical trials in patients with decompensated cirrhosis.
Baseline characteristics
of patients
 Include demographic data, previous complications of cirrhosis, etiology and characteristics of liver disease and liver function
tests.
 Prognostic scores such as MELD, MELD-Na and/or CTP (consider CLIF-C AD or CLIF-C ACLF)
 Important to include comorbidities such as obesity, diabetes mellitus, arterial hypertension, cardiovascular disease or chronic
kidney disease
Confounding factors  It is important to include data on variables that may act as confounding factors in this population, such as alcohol consumption/
abstinence during study period, presence or placement of TIPS, etiologic treatment (i.e., antivirals, corticosteroids for autoimmune
hepatitis).
Endpoints  Primary and all secondary endpoints should be carefully detailed and defined.
 Report absolute numbers and proportions of patients with response in each treatment arm
 Describe both absolute changes and percent changes for efficacy-related endpoints
Statistics  Planning of statistical analysis should be performed before starting the trials.
 Description of expected and timing of interim analysis and stopping rules should be defined.
 Consider the need for competing-risk or time-dependent analysis according to the trial design.
Safety data  Treatment-related adverse events should always be included
 Complications of cirrhosis and any other adverse events
 Any other specific adverse events related to the characteristics of the study treatment
CLIF-C ACLF, EASL-CLIF consortium acute-on-chronic liver failure; CLIF-C AD, EASL-CLIF consortium acute decompensation; CTP, Child-Turcotte-Pugh; MELD, model for end-
stage liver disease; MELD-Na, MELD-sodium; TIPS, transjugular intrahepatic portosystemic shunt.
Table 2. Recommendations on characteristics of the target population and endpoints for the design of clinical trials aimed at investigating new strategies
to modify the natural history of decompensated cirrhosis.
Target population
Inclusion criteria  Patients with cirrhosis defined by standard clinical criteria, ultrasonographic findings and/or histology.
- Decompensated cirrhosis with CTP score B or C up to 12 points (a subgroup of CTP A patients may have decompensated
cirrhosis; in particular those with moderate ascites and preserved hepatic function).
 No upper limit for age
 Patients on the waiting list for liver transplantation should be included
Exclusion criteria  Active alcohol consumption expected to preclude correct adherence to study procedures
 Patients with a history of significant non-hepatic diseases with impaired short-term prognosis (heart failure NYHA Grade III/IV,
COPD GOLD C or above).
 Patients with current non-hepatic malignancies including solid tumours and hematologic disorders.
 Patients with hepatocellular carcinoma, except for patients with early HCC (BCLC-0 or BCLC-A) or patients with previous history
of HCC and absence of recurrence 2 years after treatment.
 Patients on antiviral therapy for HCV or those who have received it within the last 12 months. Patients with antiviral therapy for
HBV for less than 12 months.
 Patients under treatment with corticosteroids for autoimmune hepatitis for less than 6 months.
 TIPS insertion within 6 months prior to study inclusion.
Endpoints – phase III trials
Primary endpoint  Survival (90-day, 1-year)
Secondary endpoints  Composite endpoint of complications of cirrhosis
 Development of ACLF
 Hospital readmissions
 Treatment-related adverse events
Endpoints – phase II trials
Primary endpoint  Surrogate markers with known association with survival (i.e., changes in CTP or MELD score)
Secondary endpoints  Biomarkers of disease progression known to correlate with hard clinical endpoints (i.e., cytokines, oxidized albumin, NGAL or
other biomarkers).
 Treatment-related adverse events
ACLF, acute-on-chronic liver failure; COPD, chronic obstructive pulmonary disease; CTP, Child-Turcotte-Pugh; GOLD, Global Initiative for Chronic Obstructive Lung Disease;
HCC, hepatocellular carcinoma; MELD, model for end-stage liver disease; NGAL, neutrophil gelatinase-associated lipocalin; NYHA, New York Heart Association; TIPS, trans-
jugular intrahepatic portosystemic shunt.
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Position Paperdisease, namely ascites, GI bleeding, HE or jaun-
dice. These patients are also at risk of bacterial
infections or AKI.18,19 Patients with decompensated
cirrhosis usually belong to Child-Turcotte-Pugh
(CTP) class B or C, corresponding to a CTP score >−7
points (Table 3). However, there are exceptions to
this rule. First, a subgroup of patients rated as CTP
class A may have decompensated cirrhosis if they
have moderate ascites or grade I-II HE with pre-
served liver function. Another exception to this
classification is patients with significantly impaired
liver function (i.e. serum bilirubin 2–3 mg/dl)
without clinical complications, that may beJournal of Hepatology 2021 vol. 74 j 2classified as CTP class B but would strictly fit in the
category of compensated cirrhosis.
CTP classification has pitfalls because of the
subjective nature of assessment of ascites and HE. It
is also a categorical classification for a clinical con-
tinuum. On the other hand, the CTP classification is a
widely used, easy to calculate and validated tool that
can be applied for classification and stratification of
patients with decompensated cirrhosis in clinical
trials.20 In order to minimise subjectivity, it is rec-
ommended to strictly follow the original CTP clas-
sification to grade the clinical and laboratory
variables adequately.21 Another aspect that should00–219
Table 3. Child-Turcotte-Pugh scoring system.
1 2 3
Hepatic encephalopathy None Mild to moderate (grade 1–2) Severe (grade 3–4)
Ascites None Mild to moderate (diuretic-responsive) Severe (refractory)
Bilirubin (mg/dl) 1–2 mg/dl 2–3 mg/dl >3 mg/dl
Albumin (g/dl) >3.5 g/dl 2.8–3.5 g/dl <2.8 g/dl
PT prolongation 1–4 s 4–6 s >6 seg
PT, prothrombin time.
The table is based on the original Child-Turcotte-Pugh scoring system except for the grading of ascites. Assessment of ascites severity is
based on subsequent modifications that are currently widely used and lead to more objective assessment of this complication.*
*see refs.20,21be considered for the design of clinical trials is that
cirrhosis is a dynamic and bidirectional disease, and
that a number of patients with previous de-
compensations may “recompensate” after etiolog-
ical treatment or specific interventions. In these
cases, it is important to note that the evaluation of
clinical decompensations and CTP calculation
should be performed at the time a patient is evalu-
ated for inclusion in a clinical trial, and only current
decompensations should be considered.
Data derived from cohorts describing the prog-
nosis of patients with cirrhosis according to CTP
class do not provide specific information on mor-
tality according to CTP score (points).1,22–25 That is,
CTP class is used to stratify patients, but cannot be
used to calibrate risk of mortality. However, clinical
experience and evidence from published studies
show that patients with very high CTP scores
(>−13 points) have a poor short-term prognosis. In
this regard, one could argue that those patients
may not benefit from the intervention tested and
that this group might unbalance the study cohort.
Recently published or ongoing randomized
controlled trials (RCTs) including patients with
decompensated cirrhosis have addressed the
issue of the inclusion of CTP C patients
differently. Some trials do not exclude patients
based on CTP score,7–9,11 whereas others have
excluded patients with high CTP scores.6,26,27 In
this regard, we recommend excluding patients
with CTP scores >−13 from trials due to their
markedly impaired prognosis. However,
exceptions could be made for short-term studies.
Stratification of study cohorts according to the
CTP score should always be considered.
Age
As a result of the aging of the general population in
the last decades and the improvement of the man-
agement and survival of patients with cirrhosis, pa-
tientswith decompensated cirrhosis tend to be older
than in the past. The exclusion of patients from
clinical trials based on an upper limit of age is a
controversial topic. To date, some published RCTs in
cirrhosis include an upper limit for age,6–8 but others
donot include this age restriction.9,11,26 Although age
influences prognosis and excluding older patients
may seem reasonable, there is no objective data to
decide which is the best cut-off to use as an upperJournal olimit of age. On this background and considering
the current demographic and clinical
characteristics of patients with decompensated
cirrhosis, we suggest that exclusion criteria should
be based on severe comorbidities rather than an
upper limit of age.
This position is also supported by the National
Institutes of Health (NIH) policy that states that
individuals of all ages must be included in all hu-
man research conducted or supported by the NIH,
unless there are scientific or ethical reasons not to
include them.
Comorbidities
Because the population of patients with cirrhosis is
getting older and given the rising incidence of non-
alcoholic steatohepatitis (NASH)-related cirrhosis,
it is expected that an increasing number of patients
with comorbidities will be evaluated for inclusion
in clinical trials of decompensated cirrhosis in the
coming years.28 A reasonable recommendation for
this scenario is to exclude patients with severe
comorbidities unrelated to liver disease that are
associated with high short-term mortality, such as
severe heart failure defined by the New York Heart
Association (NYHA) classification III and IV29; pa-
tients with severe chronic obstructive pulmonary
disease, defined by a Global Initiative for Chronic
Obstructive Lung Disease (GOLD) score of C or
above30; and patients with extrahepatic malig-
nancies with expected high short-term mortality.
Inclusion and exclusion criteria for patients with
chronic kidney disease will be discussed later in
this document (see section hepatorenal syndrome-
acute kidney injury).
HIV infection
In the past, patients with HIV infection were
excluded from clinical trials in cirrhosis because of
their poor prognosis and the risk of opportunistic
infections as well as contraindications to many
drugs and interventions because of interactions
with HIV treatment. Nowadays, patients with
chronic HIV infection under control on treatment
have a life expectancy similar to that of the
general population.31,32 Therefore, the general
recommendation is that these patients can be
included in RCTs of decompensated cirrhosis if HIV
infection is well controlled (defined as CD4 >250/f Hepatology 2021 vol. 74 j 200–219 203
204
Position Papermm3 and undetectable viral load33), and no sig-
nificant interactions are expected between the
tested drug and HIV treatment.
Active alcohol consumption
Alcohol is the most frequent cause of cirrhosis in
Europe and the US.34–36 In patients with alcohol-
related cirrhosis, alcohol consumption is a major
prognostic factor for survival.37,38 However, a
significant number of patients with alcohol-
related cirrhosis are active drinkers. Excluding
such patients from clinical trials would create a
study population quite different from what is
seen in clinical practice in many countries.
Exclusion of patients with active alcohol
consumption should be based on the amount of
alcohol that is considered by the investigator to
preclude adherence to the study protocol, as well
as factors such as psychiatric comorbidities or
personality or social issues that may affect
adherence to the study protocol. Conversely, if
patients become abstinent while on a therapeutic
trial this may result in improved survival per se
and act as a confounding factor. Therefore,
it is essential to periodically record alcohol
consumption in all patients with alcohol-related
cirrhosis included in clinical trials to enable the
correct interpretation of results.
The use of biomarkers of alcohol consumption is
recommended, if possible, to provide a more
objective assessment of alcohol consumption. Bio-
markers, which are products of the metabolism of
alcohol are highly specific and have a longer
detection window than measurement of alcohol in
body fluids or exhaled air. Among the alcohol
consumption biomarkers available, it may be
preferable to use those that are not affected by liver
disease, such as ethyl glucuronide (EtG), ethyl sul-
fate or phosphatidylethanol.39–41 Urine EtG is the
most widely used marker of alcohol consumption
in alcohol addiction programmes and on waiting
lists for liver transplantation. Moreover, its use is
recommended for confirmation and monitoring of
alcohol consumption by the European and the
American scientific society guidelines for the
management of alcohol-related liver disease.
Therefore, using biomarkers such as EtG seems a
good option for clinical trials of decompensated
cirrhosis that include patients with alcohol-
related liver disease.42,43
Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) influences the nat-
ural history of cirrhosis per se and represents a con-
founding factor in trials evaluating survival.
However, exclusion of all patients with current or
previousHCCmight restrict recruitment into studies.
The probability of progression of early HCC (BCLC-
0 and BCLC-A) within 6–12 months is very low.44,45
Therefore, patients with BCLC-0 or BCLC-A HCCJournal of Hepatology 2021 vol. 74 j 2may be included in clinical trials that require 6–12
months follow-up, as HCC is not expected to impact
survival during that period in patients with decom-
pensated cirrhosis. When considering patients with
a previous history of treated HCC, absence of recur-
rence for 2 years following completion of treatment
is generally considered as complete response. The
prognosis of these patients is good with low HCC-
related mortality over the mid to long term.46,47
Thus, these patients may also be included, as HCC
would likely not influence outcomes.
Regarding patients with intermediate stage HCC
(BCLC-B), the expected median survival without
treatment is 16 months44,48 and the presence of
impaired liver function is an accepted contraindi-
cation for locoregional therapies49 and an inde-
pendent predictive factor of poor outcome.50
Finally, in patients with severely impaired liver
function, HCC is categorized as terminal.44,49
Accordingly, patients with HCC who are BCLC
stages B-D have an unacceptable competing mor-
tality risk and their inclusion in clinical trials of
decompensated cirrhosis should not be supported.
Etiologies of cirrhosis with specific treatment: auto-
immune and viral hepatitis
Specific therapies, such as corticosteroids and
azathioprine for autoimmune hepatitis (AIH) or
antiviral drugs for HBV and HCV, may modify the
natural history of decompensated cirrhosis by
improving liver function. There is more evidence
available on this in patients with HCV-related
cirrhosis than in patients with HBV or AIH. In this
regard, although most studies have focused on the
effect of antiviral therapy on clinical de-
compensations at 6 months after treatment, there
are also studies indicating that a positive effect on
clinical decompensations may be seen after an
even longer period of time (1 or 2 years) following
antiviral treatment in a proportion of patients.
Nonetheless, improvement in portal pressure and
clinical decompensations after sustained virolog-
ical response (SVR) are less frequent in patients
with previous ascites, compared to those without
previous ascites.51–53
A period of at least 6 months after SVR in the
case of HCV or after suppression of viral replication
in the case of HBV may be sufficient to avoid the
interference of the effect of the etiological treat-
ment in clinical trials. However, in light of these
recent results, we currently propose waiting a 12-
month period after SVR in patients with HCV or
after control of infection in HBV before including
these patients in clinical trials. In the case of AIH
there is less evidence of favourable response and
resolution of clinical decompensations after
immunosuppressive therapy; however, a period of
at least 6 months after obtaining clinical and
biochemical remission under immunosuppressive
therapy seems reasonable before including these00–219
patients in clinical trials of decompensated
cirrhosis. It is important to note that a number of
patients may experience resolution of their clinical
decompensations after removal of the cause of
cirrhosis. In this regard, the evaluation of the
clinical status and stage of the disease of patients
with cirrhosis must be performed when patients
are considered for inclusion in the clinical trial.
Patients in whom ascites resolves after cure of HCV
should not be considered as candidates for trials of
decompensated cirrhosis. The same holds true for
patients with alcohol-related cirrhosis with ascites
resolution after alcohol abstinence.37,54,55
Patients awaiting liver transplantation
Patients on the waiting list for liver transplantation
should not be excluded from clinical trials of
decompensated cirrhosis because this would
represent a selection bias by excluding patients
with the most advanced liver disease. However,
some aspects should be considered when including
this type of patient, because liver transplantation
represents a competing event. One solution is to
consider liver transplantation and death as
competing-risk events (see below). However, it
should be mentioned that time to liver trans-
plantation in patients with decompensated
cirrhosis varies in different countries based on the
organ allocation systems, donor availability and
other factors independent of the severity of
liver disease.56,57 Therefore, consideration of
liver transplantation as a competing risk in clinical
trials may cause some unavoidable biases in the
analysis of the primary endpoint of the studies. A
country-based stratification may help alleviate this
issue.
Transjugular intrahepatic portosystemic shunt
TIPS has been shown to improve survival and reduce
decompensation episodes in a proportion of patients
with decompensated cirrhosis.10,58–60 There are 2
major concerns regarding the inclusion of pati-
ents with TIPS in clinical trials of decompensated
cirrhosis: (i) TIPS placement changes the natural
history of cirrhosis; and (ii) access to TIPS is strongly
dependent on physician preference and centre’s
expertise. However, excluding all patients who have
received TIPS may greatly restrict the selection of
the study population, and results of RCTs may not
be applicable to a significant proportion of patients
with decompensated cirrhosis. A balanced solution
would be to include patients that still meet the
criteria for decompensated cirrhosis a minimum of
6 months after TIPS placement. When included in
such studies, patients may be stratified according to
the presence or absence of TIPS.
Endpoints
The distinction between phase II and phase III trials
is important to define the best primary endpointsJournal ofor clinical trials of patients with decompensated
cirrhosis.
Phase III trials
Primary endpoint: Considering the poor prognosis
of patients with decompensated cirrhosis, trans-
plant-free survival is recommended as the primary
endpoint for these studies. Transplant-free survival
is a hard and objective primary endpoint. More-
over, it is the most valuable result that can be ex-
pected of a specific intervention or drug therapy.
For this reason, survival has been the primary
endpoint in some previous clinical trials in patients
with decompensated cirrhosis.7,9,11 In addition,
overall survival should always be assessed in these
trials, and patients should be followed up to the
end of the trial regardless of protocol adherence.
Although survival is the ideal primary endpoint in
these types of studies, it is not always feasible
because of the requirement for a large sample size.
In this situation we recommend a composite
endpoint of complications of cirrhosis or develop-
ment of ACLF as a “surrogate” primary endpoint.
If either transplant-free survival or another
“surrogate” primary endpoint is used, overall sur-
vival may be used as a co-primary endpoint. In this
case, if the results of transplant-free survival or the
surrogate endpoint are positive, there would likely
be no detrimental effect derived from an overall
survival analysis.
Secondary endpoints: A composite endpoint
should include all complications that are known to
influence the quality of life and prognosis of pa-
tients with cirrhosis, such as ascites or refractory
ascites, HE, GI bleeding, bacterial infections, AKI
and jaundice. There are some pitfalls when using
this composite endpoint because each complica-
tion of cirrhosis confers a different prognosis. This
is not to say that some of these complications are
not clinically meaningful. We recommend
including these complications as secondary end-
points; they might also represent a surrogate for
poor survival. Therefore, if a composite endpoint of
complications of cirrhosis is used, worsening of a
current decompensation or the onset of a new
decompensation needs to be well defined to
minimise possible subjectivity in the interpretation
of outcomes. We propose a summary of the defi-
nitions of each decompensation event that should
be included in this composite endpoint (Table 4).
ACLF development is another possible secondary
endpoint that can be used in this setting because of
its association with mortality. Although there is no
global consensus on the definition of ACLF, based on
criteria of the different international societies (EASL,
NACSELD, APASL),61–63 overall ACLF is characterized
by a clinical decompensation of cirrhosis that is
severe enough to be associated with organ failures
and poor prognosis. If ACLF development is used as
a secondary endpoint, the possible bias of using a
composite endpoint of complications could bef Hepatology 2021 vol. 74 j 200–219 205
Table 4. Definition of the decompensations to be included in a composite endpoint of complications of cirrhosis.
Complication Definition
Ascites New onset ascites, development of refractory ascites or worsening of ascites (defined as need
for large-volume paracentesis).
Hepatic encephalopathy Development of acute episode of HE grade 2 or greater, according to West Haven criteria.
Gastrointestinal bleeding Portal hypertension-related bleeding requiring hospital admission.
Bacterial infections Proven infections using standard definitions*
Acute kidney injury Development of AKI stage 1B or greater or HRS-AKI**




Position Paperavoided. However, using ACLF as an endpoint in
clinical trials might also have some pitfalls. First,
ACLF may not always be easily identified and
diagnosed if it is not specifically looked for. Second,
advances in palliative care in decompensated
cirrhosis currently enable a significant percentage
of patients to receive medical or nursing care at
home or in nursing homes. In these cases, it may
be difficult to obtain the information required to
diagnose ACLF in these patients. Therefore, we
propose using onset of ACLF as an endpoint when
data are available to make the diagnosis; or liver-
related death when patients with decompensated
cirrhosis die in terminal care facilities.
Hospital readmissions per se should not be
considered as a primary endpoint or part of a com-
posite endpoint in trials assessing the natural history
of the disease because of susceptibility to multiple
biases. Readmission criteria are different across
countries and health systems and depend on the
social support of the patient and other factors not
necessarily related to the severity of liver disease.
Nonetheless, readmissions per se should be consid-
ered as part of the secondary endpoints as they are
clinically meaningful and reflect the effect of a spe-
cific interventionon the recurrence of complications.
However, elective readmissions (i.e., HCC therapy,
large-volume paracentesis [LVP], endoscopic band
ligation, among others) should be excluded.
Phase II trials
In phase II trials, the primary endpoint should
focus on finding some specific signals of the effect
of the drug or intervention under investigation. In
proof-of-concept studies, it is important to include
robust surrogate markers closely associated with
hard clinical endpoints (ideally with survival). To
this end, prognostic scores for survival in cirrhosis
can be useful, i.e. changes in MELD, MELD-Na or
CTP scores.64–66 Although there is less evidence
available, changes in the CLIF-C score could also
be considered.67
In this scenario, change in hepatic venous pres-
sure gradient (HVPG) is a useful endpoint in phase II
trials in decompensated cirrhosis, as previous lon-
gitudinal studies have shown that HVPG reductions
in response to therapy are predictive of clinically
relevant outcomes, such as development of ascites,
GI bleeding, encephalopathy and death.68–70Journal of Hepatology 2021 vol. 74 j 2However, the use of this tool as an endpoint in
phase II trials may be limited to centres with
specialized hepatic haemodynamic units.
In addition, biomarkers of disease progression
can be considered as possible candidate endpoints
in this type of studies. In this context, biomarkers
such as neutrophil gelatinase-associated lipocalin
(NGAL) correlate with hard clinical endpoints.71–73
However, more information is required before
accepting biomarkers as surrogate endpoints of
disease progression/impairment.
Phase IIa clinical trials are pilot studies per-
formed in a relatively small number of patients in
order to obtain efficacy signals and determine safety
of the investigational drug. A placebo group is not
required for this phase of the study. Phase IIb clinical
trials are pivotal well-established controlled trials
performed on a larger number of patients in order to
judge the efficacy and safety of the investigational
drug. A placebo or control arm is desirable in phase
IIb trials. Whenever feasible, depending on the na-
ture of the intervention, treatment arms should be
blinded to minimise possible bias.
It is necessary to comment on the importance of
safety analysis of investigational agents in patients
with decompensated cirrhosis. As cirrhosis is asso-
ciated with abnormalities in drug metabolism,
proof-of-concept studies should consider including
pharmacokinetic analysis of the interventional drug,
as well as recording information about possible in-
teractions with other drugs. Adverse events related
or unrelated to the study medication should always
be assessed. Drug-induced liver injury and drug-
induced kidney injury may be more difficult to di-
agnose in patients with decompensated cirrhosis
with underlying hepatic and renal dysfunction.Trials assessing interventions for the
management of specific complications of
cirrhosis
Ascites
Based on data from previous clinical trials10,74–81
patients require a different therapeutic approach
depending on the phenotype of ascites. When
designing trials to assess new interventions for
the management of ascites, patients should be
divided based on 2 major phenotypes: i) diuretic-
responsive ascites, and ii) refractory or recurrent00–219




Inclusion criteria  Stable, outpatients with either persistent grade 2 ascites or patients with grade 2 ascites responding to diuretic treatment (no
specific diuretic dose required).
Exclusion criteria  Patients with TIPS
 Consider all other exclusion criteria described in Table 2.
Endpoints
Primary endpoint  Worsening of ascites defined as the need for LVP.
Secondary endpoints  Survival
 Time to LVP
 Number of patients evolving from grade 2 to grade 3 ascites and development of refractory ascites
 Hospitalizations for ascites
 Diuretic-related complications or development of other complications of cirrhosis (SBP, AKI, hyponatremia)
 Health-related quality of life
 Treatment-related adverse events
Refractory ascites
Target population
Inclusion criteria  Patients with refractory ascites as defined by currently accepted definition*
Exclusion criteria  Patients with TIPS
 Consider all other exclusion criteria described in Table 2.
Endpoints
Primary endpoint  Total number of LVP over a certain period of time or time to first LVP
Secondary endpoints  Survival
 Development of other complications of cirrhosis (SBP, AKI, hyponatremia) and/or sarcopenia
 Health-related quality of life
 Treatment-related adverse events
AKI, acute kidney injury; LVP, large-volume paracentesis; SBP, spontaneous bacterial peritonitis; TIPS, transjugular intrahepatic portosystemic shunt.
*see Table S1 and reference.82ascites. The characteristics and endpoints of these
trials will depend on the target population (Table 5).
Diuretic-responsive ascites
Target population. Based on the rationale for the
management of uncomplicated ascites82,83 and data
derived from previous clinical trials in the
field,76,78–81 we recommend including outpatients
with diuretic-responsive ascites. A point of debate
is whether a minimum diuretic dose should be
required for patients to be included in these trials
as this has been used as an inclusion criterion in
some but not all trials.8,11 There is no evidence to
support using a minimum threshold of diuretic
dose as an inclusion criterion. However,
considering that guidelines do not recommend
diuretic treatment for patients with grade 1
ascites and that the natural history of these
patients is not well known,82 patients with grade
1 ascites should not be included in trials.
Therefore, we recommend a target population that
includes patients with persistent grade 2 ascites
responding to diuretic treatment, who do not
require LVP. Finally, considering that TIPS modifies
the pathophysiology of portal hypertension,
increases renal sodium excretion and may
improve prognosis,84–86 patients with TIPS should
be excluded from trials assessing interventions for
the management of ascites. In this regard, there is
some controversy about the possibility of
including patients with ascites who had previousJournal oTIPS that is occluded or has failed. Although this
could be a possibility, we believe the best option
is to exclude these patients to completely rule out
a possible residual effect of TIPS on the control of
ascites.
Endpoints. Previous trials have used response to
treatment as the primary endpoint, defined as
either an improvement or worsening of asci-
tes.76,78–81 We recommend worsening of ascites as
the most clinically relevant and unbiased primary
endpoint. However, the definition of this
endpoint is challenging as there are no
homogeneous criteria and it may introduce some
degree of subjectivity. The primary endpoint
should be defined in such a way that it reflects a
clinical deterioration leading to the need for a
change in the management of ascites. Among all
definitions of worsening of ascites used in the
past,76,78–81,87 there was an agreement that this
endpoint should be defined as “need for LVP to
relieve intense abdominal discomfort”.
Finally, other data such as survival, health-
related quality of life (HRQOL) and cost-effective-
ness are recommended as the most important
secondary endpoints in these trials. Other second-
ary endpoints that should also be assessed are time
to LVP; number of patients progressing from grade
2 to grade 3 ascites; development of refractory
ascites; hospitalizations for ascites; diuretic-related
complications; development of other complica-
tions of cirrhosis (spontaneous bacterial peritonitisf Hepatology 2021 vol. 74 j 200–219 207
Table 6. Recommendations on characteristics of the target population and endpoints for the design of clinical trials evaluating interventions for the
management of hypervolemic hyponatremia.
Target population
Inclusion criteria  Patients with decompensated cirrhosis and hypervolemic hyponatremia defined as serum sodium <130 mmol/L, irrespective of
the presence of symptoms.
Exclusion criteria  Hypovolemic hyponatremia
 Diseases that may induce hyponatremia other than cirrhosis (i.e., hypothyroidism, heart failure, chronic kidney disease, SIADH)
 Drug-induced hyponatremia
 AKI stage 1B* or above
 Patients with hepatic encephalopathy grade 2 or above
 Consider all other exclusion criteria described in Table 2.
Endpoints
Primary endpoint  Improvement of hyponatremia defined as increase in serum sodium levels of at least 5 mmol/L.
Secondary endpoints  Pre and post liver transplant survival
 Occurrence of hepatic encephalopathy
 Health-related quality of life
 Treatment-related adverse events
AKI, acute kidney injury; SIADH, syndrome of inappropriate antidiuretic hormone secretion.
*AKI 1B: patients with AKI stage 1 and serum creatinine at diagnosis >1.5 mg/dl (reference82).
208
Position Paper[SBP], AKI, hyponatremia); or treatment-related
adverse events.
Refractory or recurrent ascites
Target population. Trials should include patients
with refractory ascites as defined by the currently
accepted definition (see Table S1).82 However,
because the diagnostic criteria for refractory ascites
may be too stringent, the target population of these
studies may be modified by adding patients who,
despite not meeting the criteria for refractory as-
cites, develop recurrent large-volume ascites
requiring LVP (more frequently than 3 times a
year). Patients with TIPS should be excluded.
Endpoints. Although survival is a strong primary
endpoint it should probably not be the primary
endpoint of choice in these trials. Interventions for
the management of refractory ascites may not in-
crease survival, particularly in patients who are not
candidates for liver transplantation, but may
improve the control of ascites or HRQOL,88–90
which are clinically meaningful endpoints in this
population.
Most previous clinical trials that have assessed
interventions for the management of refractory as-
cites have used either total number of LVP/total
volume of ascites removed over a certain period of
time, or time to first LVP, to assess response to
treatment.10,58,74,75,77,91 There is agreement that
these are the most appropriate primary endpoints
to use in trials. In addition, other relevant endpoints
such as survival, HRQOL, other complications of
cirrhosis (SBP, AKI, hyponatremia, hepatic hydro-
thorax) and sarcopenia are recommended as sec-
ondary endpoints. A summary of recommendations
for refractory ascites is provided in Table 5.
Hyponatremia
There is a large body of evidence showing that
hyponatremia is not just a laboratory abnormality,
but is associated with relevant clinical outcomes
such as increased risk of HE and impaired quality of
life in patients with decompensated cirrhosis.92,93Journal of Hepatology 2021 vol. 74 j 2In addition, hyponatremia is associated with
increased mortality both before and after liver
transplantation.65,94–96 Thus, hyponatremia is
considered a relevant complication of cirrhosis
that has an important impact on patient
outcomes and, therefore, should be included as a
complication requiring therapy.
The distinction between hypovolemic and
hypervolemic hyponatremia in patients with
cirrhosis is crucial, not only from a theoretical point
of view but also from a therapeutic perspective. In
this consensus document, we focus only on studies
that include patients with cirrhosis and hyper-
volemic or dilutional hyponatremia (Table 6).
Target population
Although the threshold for defining hyponatremia
in the general population is established as serum
sodium below 135 mmol/L,97 classically, in patients
with cirrhosis, hyponatremia has been arbitrarily
defined as serum sodium <130 mmol/L.98,99
Nonetheless, studies investigating therapeutic
strategies for the management of hyponatremia
and the impact of hyponatremia on clinical out-
comes have used heterogeneous criteria. Some
have included patients with serum sodium <130
mmol/L, while others have mainly included pa-
tients with serum sodium <135 mmol/L.93,100 To
use homogeneous criteria in future trials evalu-
ating therapeutic options for the management of
hypervolemic hyponatremia it may be appropriate
to include patients with serum sodium <130 mmol/
L, irrespective of the presence of symptoms. We
suggest that clinical trials should stratify patients
according to the severity of hyponatremia by using
<125 mmol/L as a cut-off level, as it has been
defined in previous studies.100–102
Exclusion criteria. It is essential to rule out the
presence of hypovolemic hyponatremia. In addi-
tion, we recommend that patients with diseases
other than cirrhosis that may induce hyponatremia
should be excluded (i.e., hypothyroidism, heart
failure, chronic kidney disease, syndrome of00–219
Table 7. Recommendations on characteristics of the target population and endpoints for the design of clinical trials
evaluating interventions for the management of HRS-AKI.
Target population
Inclusion criteria  Patients with HRS-AKI defined according to the definition included in current clinical practice
guidelines*
Exclusion criteria  Consider all other exclusion criteria described in Table 2.
 Patients with baseline CKD should not be excluded.
Endpoints
Primary endpoint  Complete response to treatment defined according to current guidelines: decrease in SCr to a
value within 0.3 mg/dl (<−26.5 mmol/L) of the baseline value
Secondary endpoints  Partial response to treatment: reduction by at least 1 AKI stage with decrease of SCr to
>−0.3 mg/dl (>−26.5 mmol/L) above the baseline value. Decrease in serum creatinine values: 30% decrease in SCr with respect to pre-treatment value
 Survival (in-hospital, 28-day and 90-day)
 Need for renal replacement therapy
 Recurrence of HRS-AKI after treatment
AKI, acute kidney injury; CKD, chronic kidney disease; HRS-AKI, hepatorenal syndrome-acute kidney injury; SCr, serum creatinine
concentration.
*Reference.82inappropriate antidiuretic hormone secretion).
Moreover, other clinical conditions that can cause
or modify the course of hyponatremia should be
ruled out (i.e., use of psychotropic drugs). Finally,
patients with significant AKI (AKI 1B or greater,
defined as AKI stage 1 with creatinine at diagnosis
>−1.5 mg/dl, see definition in section 2.3) and pa-
tients with HE grade 2 or above according to the
West Haven criteria103 should be excluded from
these trials.
Endpoints
Based on criteria used in previous trials,104–106 we
recommend that the primary endpoint should be
resolution of hyponatremia. Nonetheless, there is
no accepted definition for resolution of
hyponatremia in clinical trials including patients
with cirrhosis. Previous clinical trials, either in
the general population or in patients with
cirrhosis, have based the definition of resolution
of hyponatremia on: i) changes in serum
sodium concentration with respect to baseline;
and/or ii) achieving normal serum sodium
concentration.79,100,105–107 Considering that
baseline serum sodium concentration may be
very low in some patients with decompensated
cirrhosis (i.e. <125 mmol/L) we believe using a
final sodium threshold of >−135 mmol/L for
resolution of hyponatremia may be too stringent.
We propose the concept of partial response, to
refer to those patients with an increase of serum
sodium levels of at least 5 mmol/L irrespective of
the final value of serum sodium, and complete
response for those who achieve levels of serum
sodium >130 mmol/L.
Secondary endpoints. Hyponatremia is an important
risk factor for increased morbidity and mortality in
cirrhosis. There is a large amount of data showing
that hyponatremia is a risk factor for the develop-
ment of HE and that it is also associated with
impaired quality of life and pre- and post-trans-
plant mortality.65,92,95 Based on this evidence, we
recommend that studies aimed at assessing the
efficacy of different therapies for improvement ofJournal ohyponatremia should include pre- and post-liver
transplant survival, improvement of quality of life
and occurrence of HE as secondary endpoints.
Time-to-correction of hyponatremia may also be
included as a secondary endpoint. Importantly, it is
well known that correcting hyponatremia too
rapidly may lead to severe neurological disorders
in patients with cirrhosis108 (i.e., osmotic demye-
lination syndrome – formerly known as central
pontine myelinolysis or CPM). Therefore, including
treatment-related adverse events as secondary
endpoints in these trials is mandatory.Hepatorenal syndrome-acute kidney injury
Patients with cirrhosis may develop different types
of AKI.107,109 Hepatorenal syndrome-acute kidney
injury (HRS-AKI) is a characteristic type of AKI in
patients with decompensated cirrhosis and is the
only type of AKI that has a specific treatment.82,110
For the purposes of this document we focus only
on trials assessing interventions for the manage-
ment of HRS-AKI (see Table 7).
Target population
The definition of AKI and, consequently, the defi-
nition of HRS-AKI has recently been modified.111,112
Therefore, patients included in clinical trials of
HRS-AKI should meet the definition included in
current clinical practice guidelines82 (see Tables S2
and S3).
Before including patients into clinical trials, the
presence of AKI due to causes other than HRS must
be ruled out. Recently, novel kidney biomarkers
have emerged in this setting to help differentiate
between HRS-AKI and acute tubular necrosis, with
NGAL being the most promising.73,82,113–117
Although biomarkers are still not widely
available, we believe there is sufficient evidence
supporting kidney biomarkers, particularly NGAL,
to warrant discussion about their incorporation
into the algorithm for the differential diagnosis of
HRS-AKI.82 They may also be recommended as
inclusion criteria in future clinical trials.f Hepatology 2021 vol. 74 j 200–219 209
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AKI can develop in patients with baseline chronic
kidney disease (CKD). In addition, given the
increasing number of patients with NASH-related
cirrhosis, there has been a progressive increase in
the prevalence of patients with cirrhosis and CKD.
Since the frequency of patients with CKD may be
high, we recommend not excluding these patients
from clinical trials evaluating HRS-AKI. Moreover,
several studies have shown that baseline serum
creatinine (SCr) levels are a predictive factor for
response to treatment.118 We recommend strati-
fying patients at randomization according to
baseline CKD or by baseline SCr levels.
Finally, a recent study reported that the pres-
ence and severity of ACLF has a negative impact on
response to treatment in patients with HRS-AKI.119
In fact, patients with the most severe ACLF, namely
ACLF grades 2 and 3 (2 or 3+ organ failures,
respectively), had a lower probability of response
to terlipressin and albumin compared to patients
with ACLF grade 1. We suggest that in future clin-
ical trials that include patients with HRS-AKI, pa-
tients should be stratified according to the
presence and severity of ACLF at randomization.
Endpoints
It should be noted that, to date, none of the clinical
trials evaluating the efficacy of treatment for HRS
have included patients with HRS-AKI according to
the new definition. Therefore, all recommenda-
tions are based on previous trials including pa-
tients with classical type-1 HRS.109,120–124
The primary endpoint for trials evaluating new
strategies for the management of HRS-AKI should
be complete response to treatment, which is the
primary endpoint that has been widely used in
previous trials in the field.109,120–124 According to
guidelines, treatment should be maintained until
complete response or for a maximum of 14 days
in the case of partial response or non-response.82
Complete response should be defined according
to current guidelines as the decrease in SCr to a
value within 0.3 mg/dl (<−26.5 lmol/L) of the
baseline value. Partial response to treatment
should be included as a secondary endpoint and be
defined as regression of at least 1 AKI stage with a
reduction of SCr to >−0.3 mg/dl (>−26.5 lmol/L) above
the baseline value.82 Previous clinical trials evalu-
ating the efficacy of treatment for type-1 HRS have
used a percentage decrease in SCr as a secondary
endpoint.124 This variable has been shown to be
associated with mortality. Therefore, it is suggested
that a 30% decrease in SCr with respect to pre-
treatment value may be included as a secondary
endpoint.
Survival should also be included as a secondary
endpoint (in-hospital, 28-day and 90-day survival).
It is important to note that in the setting of patients
with HRS-AKI, renal replacement therapy (RRT)Journal of Hepatology 2021 vol. 74 j 2and liver transplant influence short-term survival.
Therefore, a survival assessment which accounts
for these competing events (RRT, liver transplant)
is necessary for such trials. Other variables that we
recommend including as secondary endpoints are
need for RRT and recurrence of HRS-AKI after
treatment.
Bacterial infections
As far as trials specifically evaluating strategies for
the management of bacterial infections are con-
cerned, two types of trials with different patient
populations can be considered: prophylactic trials
and therapeutic trials. A summary of the recom-
mendations is provided in Table 8.
Prophylactic trials
Target population. Prophylactic trials should include
patients at high risk of developing bacterial in-
fections. Currently, there is evidence of different
populations at high risk of developing bacterial
infections: i) patients with ascites and low protein
content in ascitic fluid (<1.5 g/dl) and CTP class B or
C7; ii) patients with variceal bleeding125; iii) pa-
tients surviving an episode of spontaneous bacte-
rial peritonitis126; iv) patients with ACLF127; v)
hospitalized patients at risk of nosocomial
infections.128
Endpoints in prophylactic trials. The most appro-
priate primary endpoints for prophylactic trials
are: i) time to the development of bacterial in-
fections or ii) total number of infections during
study period. The former would be more appro-
priate for short-term studies, while the latter
would be appropriate for long-term studies. Death
or liver transplant during follow-up should be
considered as a potential competing risk for the
development of infections.
Bacterial infections should be identified and
diagnosed according to international standardized
diagnostic criteria129 (Table S4). Ideally, suspected
but unproven infections should not be counted as
endpoints in this setting.
The severity of infections, as defined by the
occurrence of sepsis and/or septic shock, may be
included as a secondary endpoint in prophylactic
trials. The criteria for sepsis have recently been
modified and are based on the sepsis-3 and quick
sequential organ failure assessment (qSOFA)
criteria, which have been validated in some
groups of patients with cirrhosis. A diagnostic
algorithm for the application of Sepsis-3 and
qSOFA has been suggested130 and is recom-
mended for use in this setting (Fig. S1). We
recommend diagnosing septic shock according to
Sepsis-3 criteria.
Other clinically relevant information that we
recommend analysing as secondary endpoints in
prophylactic trials include: i) survival, and ii)
development of organ failures and ACLF.00–219
Table 8. Recommendations on characteristics of the target population and endpoints for the design of clinical trials
evaluating interventions for the management of bacterial infections.
Prophylactic trials
Target population
Inclusion criteria  Patients at high risk of developing bacterial infections:
- patients with ascites and low protein content in ascitic fluid (<1.5 g/dl),
- patients with variceal bleeding,
- patients surviving an episode of spontaneous bacterial peritonitis,
- patients with acute-on-chronic liver failure,
- hospitalized patients surviving an episode of bacterial infection (at risk for nosocomial
infections)
Exclusion criteria  Consider exclusion criteria described in Table 2.
Endpoints
Primary endpoint  Time to the development of infections or total number of infections during study period
Secondary endpoints  Survival
 Development of sepsis or septic shock
 Development of organ failures
 Treatment-related adverse events
Therapeutic trials
Target population
Inclusion criteria  Patients with decompensated cirrhosis and bacterial infections*
Exclusion criteria  Consider all other exclusion criteria as described in Table 2.
Endpoints
Primary endpoint  Resolution of infections defined as clinical cure ± microbiological cure*
Secondary endpoints  Survival (30-day, 90-day)
 Development of sepsis or septic shock
 Development of AKI and other organ failures
 Number of further hospitalizations during follow-up
 Treatment-related adverse events
AKI, acute kidney injury.
*see Table S4.Therapeutic trials
Target population. According to the type of trial, the
population may include a single type of infection;
patients with different types of infection but with a
high risk ofmortality (such as sepsis or ACLF); and/or
patients at high risk of treatment failure. Standard
criteria should be used to diagnose infections (see
Table S4). Patients with suspected but unproven in-
fections could be included in trials while awaiting
results of cultures. Thereafter, if cultures are nega-
tive, two different options are possible: i) exclude
these patients from the analysis, or ii) stratify the
final analysis by suspected/culture-negative in-
fections vs. proven/culture-positive infections.
Endpoints for therapeutic trials. The optimal pri-
mary endpoint for therapeutic trials aimed at
treating infections (such as those assessing
new antibiotics) is the resolution of infection.
The definition of infection resolution can rely
on two concepts: clinical cure and microbiological
cure.131
Clinical cure is defined as the investigator’s
assessment of clinical response and is based on the
resolution of signs and symptoms of infection and
clinical improvement. However, there is no
consensus definition of clinical cure, which can
lead to potential bias and lack of reliability. The use
of an adjudication committee with pre-specified
criteria may reduce this bias. The sequential use of
biomarkers such as CRP or procalcitonin may be
useful. Data on the evolution of CRP levels during
the course of infections in patients with cirrhosisJournal osuggests that it could be a useful tool to guide
adjudication.132
Microbiological cure is defined by negative
cultures. It is more objective than clinical cure, but
it is limited by the low rate of culture positivity in
patients with cirrhosis and bacterial infections
(particularly in SBP and pneumonia – 50–65%).
Thus, microbiological cure may be a good endpoint
for urinary tract infections and bloodstream in-
fections, while clinical cure may be more suitable
for pneumonia. Suggested definitions for resolu-
tion of infection based on current guidelines or FDA
recommendations are shown in Table S5. Specific
time points for the assessment of clinical cure and/
or microbiological cure should be pre-specified
according to the characteristics of the study treat-
ment. Time to clinical/microbiological cure can also
be used as a secondary endpoint.
Other secondary endpoints should include 28-
day and 90-day mortality, development of AKI and
other organ failures (ACLF) and number of further
hospitalizations during follow-up.
Studies aimed at preventing or treating in-
fections with antibiotics in patients with cirrhosis
could potentially select multidrug resistant (MDR)
bacteria, a particularly relevant concern in some
parts of the world.133,134 We suggest considering
the development of infections due to MDR bac-
teria a potential secondary endpoint for both
prophylactic and therapeutic trials.9 Studies in the
general hospital population indicate that the
acquisition of carrier status could be relevant forf Hepatology 2021 vol. 74 j 200–219 211
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paucity of studies in patients with cirrhosis there
is not enough evidence to suggest that MDR car-
riage could be considered as a secondary
endpoint.
Hepatic encephalopathy
RCTs evaluating HE should take into account that
this complication is heterogeneous and dynamic,
making classification difficult.135,136 Clinical trials
in HE may be categorized as: i) therapeutic trials to
reverse episodes of overt HE (OHE); ii) trials to
prevent OHE; and iii) trials in covert HE.137 Covert
HE will not be covered in the current position pa-
per. A summary of recommendations for clinical
trials on HE is provided in Table 9.
Therapeutic trials focused on reversing episodes of
overt HE
Target population. To have an homogeneous popu-
lation we recommend including patients with OHE,
that is patients with grade 2 (with temporal
disorientation or asterixis) to grade 4 (coma) HE,
according to West Haven criteria.103,138,139 Because
of the need for sufficient time to exclude other
conditions that resemble HE and also to correct for
precipitating events, we recommend including
only patients with an overt episode of HE lasting
for a minimum of 24 hours. In addition, it is rec-
ommended that trials should include only hospi-
talized patients to allow for a complete assessment
of the intervention on HE.
As for the exclusion criteria, a careful exami-
nation of the patient should be performed to
exclude specific neurological conditions such as
other metabolic encephalopathies or neuropsychi-
atric diseases unrelated to liver disease.140,141
There was agreement that patients with TIPS or
spontaneous shunts should not be excluded.
Nevertheless, as their clinical course and compli-
cations may have specific characteristics, we
recommend stratifying the population according to
presence or absence of TIPS or large spontaneous
shunts. Large spontaneous portosystemic shunts
have been defined arbitrarily as a shunt with a
transversal diameter greater than 8 or 10 mm, in
different studies, or as a total shunt area greater
than 83 mm2.142–144 Although the information on
this issue is still limited, we propose using the
cut-offs of 10 mm of transversal diameter or 100
mm2 (10×10 mm) of total shunt area for patient
stratification in clinical studies on HE.
Finally, we recommend excluding patients with
ACLF grade 3, with 4 or more organ failures, due to
the poor short-term prognosis.61,145 Nonetheless,
because of the heterogeneity of patients with ACLF,
we suggest that patients should be stratified ac-
cording to presence and severity of ACLF in future
clinical trials.Journal of Hepatology 2021 vol. 74 j 2Endpoints. Complete resolution of HE defined as
the absence of OHE after a specific period of time
(i.e., 72 hours) should be the primary endpoint.
Most recent trials use time to resolution of HE as
the primary endpoint. However, we consider that
the frequency of patients achieving complete res-
olution of HE is more suitable as a primary
endpoint because it is more clinically relevant from
the patient perspective.
Secondary endpoints. Time to resolution of HE may
be considered as a secondary endpoint. Other
secondary endpoints that we recommend consid-
ering include: i) improvement of at least 2 grades
in the severity of HE according to West Haven
score; ii) length of hospital stay; iii) 28-day and 90-
day survival. Finally, changes in ammonia levels
and in neuropsychiatric test measures could also
be considered, but only as a secondary endpoint.
Clinical trials focused on prophylaxis of HE
Target population. Two different populations can be
defined within this category: i) patients who have
recovered from the first bout of OHE, for whom
standard of care is non-absorbable disaccharides;
ii) patients with recurrent HE (2 or more bouts of
OHE within 6 months), for whom the current
standard of care is non-absorbable disaccharides
plus rifaximin.103,139
Endpoints. Recent clinical trials in this setting use
either time to next episode of HE or number of
episodes of HE as a primary endpoint (see Table 9).
We consider the number of episodes of OHE
requiring hospital admissions in a defined period
of time as the most appropriate primary endpoint
for prophylactic trials. Time to the next episode of
HE and the severity of episodes of HE according to
West Haven criteria grade could be considered as
secondary endpoints.
Acute-on-chronic liver failure
One of the major issues to be addressed when
designing trials on ACLF is the lack of consensus on
diagnostic criteria. Indeed, various definitions of
ACLF have been developed worldwide,61,62,146 thus
leading to differences in the patient populations
included across studies.
Before a common definition of ACLF is arrived
at, we recommended using the most up-to-date
local definition when designing clinical trials,
according to the recommendations or consensus
of the main international scientific societies.
Nevertheless, in our opinion, taking into consid-
eration all definitions, it seems advisable to use
diagnostic criteria based on the combination of
acute decompensation of cirrhosis and at least 1
organ failure.
In the setting of ACLF, studies may be divided
according to the type of intervention: i) therapeutic
trials or ii) prophylactic trials aimed at preventing00–219




Inclusion criteria  Patients with persistent episodes of overt hepatic encephalopathy (>−24 hours) grade 2 or above according to West Haven
classification.
Exclusion criteria  Other neurological conditions (metabolic encephalopathies, neuropsychiatric diseases).
 Patients with previously known neurological or psychiatric disorders
 Normal serum ammonia levels.
 Patients with ACLF with >−4 organ failures. Patients with GI bleeding within the last 5 days.
 Consider other exclusion criteria as described in Table 2.
**Patients with TIPS or spontaneous shunts should not be excluded, except if TIPS has been performed within the last 3 months.
Endpoints
Primary endpoint  Complete resolution of HE defined as the absence of overt hepatic encephalopathy.
Secondary endpoints  Time to resolution of HE
 Survival (28-day, 90-day).
 Improvement of at least 2 grades in the staging of HE
 Length of hospital stay
 Treatment-related adverse events
Prophylactic trials
Target population
Inclusion criteria  Patients who have recovered from the first acute episode of OHE or patients with recurrent HE (>−2 episodes of acute HE in 6
months)
Exclusion criteria  Consider same exclusion criteria as for therapeutic trials.
Endpoints
Primary endpoint  Number of episodes of OHE requiring hospital admission (in a predefined period of time).
Secondary endpoints  Time to next episode of OHE
 Severity of episodes of OHE
 Survival (28-day, 90-day).
 Health-related quality of life.
 Treatment-related adverse events
ACLF, acute-on-chronic liver failure; GI, gastrointestinal; HE, hepatic encephalopathy; OHE, overt hepatic encephalopathy; TIPS, transjugular intrahepatic portosystemic
shunt.the development of ACLF in patients at risk. A
summary of the recommendations for ACLF is
provided in Table 10.
Therapeutic trials
Target population. ACLF is a very dynamic syn-
drome and is associated with high short-term
mortality. In this regard, considering the short time
frame that must be considered and the subsequent
need for large cohorts of patients, we suggest being
inclusive when selecting patients. We suggest not
excluding comorbidities or clinical conditions that
potentially only modify the long-term prognosis of
patients in the setting of ACLF.
The severity of ACLF and the number of
concomitant organ failures lead to high heteroge-
neity within study populations, with different
prognoses and mortality rates. Patients with 4 or
more organ failures have very high short-term
mortality rates, ranging from 50 to 80%.61,147,148 It
should be noted that mortality also differs ac-
cording to the type of organ failure.149 Therefore,
patients with ACLF and >3 organ failures, particu-
larly those with organ failures leading to high
mortality (i.e., respiratory failure) should be
excluded from therapeutic trials, since their short-
term mortality is exceedingly high.150 In addition,
considering the heterogeneity of this population,Journal owe suggest stratifying patients according to the
severity of ACLF.
Given the rapid clinical course of this condi-
tion,151 the time frame for including patients with
ACLF in trials warrants specific comment. Ideally,
therapeutic trials for ACLF should enter patients
into studies soon after a diagnosis is made. We
believe that a screening period of 24 hours from
diagnosis, followed by randomization and start of
treatment within the next 24 hours is reasonable
and feasible. However, in a real-life scenario, pa-
tients with ACLF are relatively frequently referred
from other hospitals to tertiary care centres a
variable period after the diagnosis of ACLF. In this
situation, if ACLF persists at the time of referral,
we recommend that patients could still be
included in therapeutic trials; however, patients
should be stratified according to the time from
the diagnosis of ACLF to the initiation of
treatment.
Endpoints. Short-term survival (i.e. in-hospital and
28-day) is the most appropriate primary endpoint
of any therapeutic trial on ACLF.
Secondary endpoints. As secondary endpoints, we
suggest including changes in ACLF stage (wors-
ening or improvement), according to the number of
organ failures and/or changes in the CLIF-SOFA
score. Although there is evidence supporting thef Hepatology 2021 vol. 74 j 200–219 213
Table 10. Recommended characteristics of the target population and endpoints for the design of clinical trials evaluating interventions for the man-
agement of ACLF.
Target population
Inclusion criteria  Use the most updated international definition for ACLF, according to the recommendations of the main international scientific
societies
Exclusion criteria  Patients with ACLF with 4 or more organ failures.
 Comorbidities or clinical conditions that modify only the long-term prognosis may not be relevant in the setting of ACLF and, thus,
patients with these conditions should not be excluded
Endpoints
Primary endpoint  Short-term survival (in-hospital and 28-day)
Secondary endpoints  Changes in ACLF stage (worsening or improvement)
 Treatment-related adverse events
ACLF, acute-on-chronic liver failure.
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after 3–7 days from diagnosis,151 we consider that
evidence is not strong enough to recommend a
specific timeframe for the evaluation of improve-
ment/worsening of ACLF in all therapeutic trials.
Therefore, a suitable secondary endpoint should be
“time to” worsening or improvement in ACLF
stages or specific organ failures.
Since liver transplantation may be an effective
therapeutic strategy in patients with ACLF, liver
transplantation should be considered a competing
event for death, and transplant-free survival should
be evaluated as a secondary endpoint.
Prophylactic trials
Because of high mortality rates in patients with
ACLF, the prevention of this condition in patients at
risk is of major relevance. Unfortunately, since the
predictive factors for ACLF development are still ill-
defined, defining the population at risk for inclu-
sion in prophylactic trials is still challenging.
Recently, two prospective observational studies
collected data about clinical and laboratory pre-
dictors of ACLF, both in outpatients25 and in hos-
pitalized patients with cirrhosis and acute
decompensation.152 However, we agree that, to
date, there is not enough evidence to propose
specific criteria to define patients at risk of devel-
oping ACLF who should thus be included in trials
aimed at evaluating prevention strategies. There-
fore, further results from multicentric prospective
trials are needed to appropriately address this
issue.
Patient-reported outcomes
When investigating a new intervention potentially
able to modify the natural history of cirrhosis or its
complications, the evaluation of patient-reported
outcomes (PROs), patient preferences and HRQOL
should also be considered. The collection of HRQOL
data is part of cost-effectiveness and cost-utility
analysis, which are increasingly recognized as a
useful guide for clinical decision-making and
health policies. Thus, we recommend that, when
designing interventional RCTs for patients with
decompensated cirrhosis, the evaluation of HRQOL
should be included, whenever possible, among
secondary endpoints. HRQOL should be directlyJournal of Hepatology 2021 vol. 74 j 2reported by patients themselves and not assessed
by an external observer or interpreted by a proxy
(e.g. clinician or caregivers) to avoid sources of
bias.153,154
Target population
HRQOL should be evaluated in any subgroup of
patients with decompensated cirrhosis. However,
HRQOL assessment may be unreliable in the pres-
ence of OHE grade II or higher; in this situation,
HRQOL evaluation should be delayed until
improvement of the patient’s cognitive status has
been reached. Similarly, patients experiencing life-
threatening complications of cirrhosis or other
complications leading to hospital admission should
be surveyed only after stabilisation of their clinical
conditions and hospital discharge.88
Tools for HRQOL assessment
Several tools are available to help quantify HRQOL
that are based on self-administered questionnaires
to evaluate a wide range of aspects of life. Ques-
tionnaires can be classified as: “generic”, applicable
to any group of patients; “disease-specific”,
designed to explore patients affected by a specific
disease; and “domain-specific” that focus on one
specific area of interest.
At present, there is insufficient evidence to
recommend the use of one tool over the others.
However, we recommend the use of a reliable and
validated generic measure (e.g. SF-36 or EQ-5 D), in
combination with a disease-specific one (e.g. CLDQ
or LDQOL).155,156 It is important to select a ques-
tionnaire for which norms are available for the
country where the study is developed. In addition,
it is advisable to avoid questionnaires with long
completion times, both because of feasibility in the
clinical context and the risk of poor patient
compliance. Similarly, there is consensus that the
use of a single questionnaire (either a robust
generic tool or a well-validated disease-specific
one) is acceptable, albeit suboptimal when HRQOL
assessment is not a primary endpoint.11,88,136
Functional and nutritional assessment
Along with classical clinical trial endpoints, a
special mention should be reserved for functional
and nutritional assessment tools. Malnutrition,00–219
sarcopenia and physical frailty often characterize
advanced phases of cirrhosis and contribute to the
impairment of patients’ HRQOL, as well as to
increased risk of complications, decompensation
and death.157–159 Consequently, we recommend
assessing sarcopenia and physical frailty at study
inclusion and using them as secondary
endpoints in clinical trials of decompensated
cirrhosis, whenever possible. A variety of
strategies and models have been proposed for
identification of sarcopenia and frailty. There
was agreement that we still cannot recommend
one preferred method based on the available
evidence. However, among different methods,
the liver frailty index has emerged as an
objective, fast and easy to perform method that
correlates with frailty and predicts mortality in
patients with cirrhosis.160,161
Other assessments
In trials evaluating new strategies for the man-
agement of patients with decompensated cirrhosis
the evaluation of cost-effectiveness is also impor-
tant (see supplementary material).
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